Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
..it's the action man.. He likes the action.. no problem
..not sure but I see posts here at 3:30 ..maybe they'll know..
$RLFTF Compassionate Care Protocol to be Conducted at Rambam Healthcare Campus in Coordination with the Government of Israel
https://infomeddnews.com/relief-therapeutics-holding-sa-announces-plans-to-test-aviptadil-for-treatment-of-covid-induced-acute-respiratory-distress-syndrome/
$RLFTF Compassionate Care Protocol to be Conducted at Rambam Healthcare Campus in Coordination with the Government of Israel
https://infomeddnews.com/relief-therapeutics-holding-sa-announces-plans-to-test-aviptadil-for-treatment-of-covid-induced-acute-respiratory-distress-syndrome/
SWX: RLF
0.56 CHF +0.10 (22.91%)
Aug 17, 12:24 PM
$RVVTF Revive Therapeutics First to Bring Oral Psilocybin Strips to the Market https://www.greenmarketreport.com/revive-therapeutics-first-to-bring-oral-psilocybin-strips-to-the-market/
$RVVTF Revive Therapeutics First to Bring Oral Psilocybin Strips to the Market https://www.greenmarketreport.com/revive-therapeutics-first-to-bring-oral-psilocybin-strips-to-the-market/
We're not even Mainstream yet... if Revive has the goods it'll make some serious noise.. the front-line is beaten down !!
Wartime doctors battling covid-19 rush to treat the ill — but without knowing what really works http://a.msn.com/01/en-us/BB181WNT?ocid=st
We're not even Mainstream yet... if Relief has the goods it'll make some serious noise.. the front-line is beaten down !!
Wartime doctors battling covid-19 rush to treat the ill — but without knowing what really works http://a.msn.com/01/en-us/BB181WNT?ocid=st
$RLFTF You Bad Boy !! - Most Read Boards
#1 Relief Therapeutics Holdings 5,222 reads last hour
#1 Relief Therapeutics Holdings 66,700 reads last 24 hours
$RVVTF 60 Minutes is showing a segment on psychedelics on tonight's episode. w/ Anderson Cooper 7pm est
-----------
Psilocybin will be on the frontline in the battles against addiction, depression and mental health.
It has growth potential in the tens of billions.
And Revive is way ahead of the game.
https://revivethera.com/2020/08/revive-therapeutics-advancing-drug-delivery-technology-for-psychedelics-developed-prototypes-of-orally-dissolvable-thin-film-for-psilocybin/
$RVVTF 60 Minutes is showing a segment on psychedelics on tonight's episode. w/ Anderson Cooper 7pm est
-----------
Psilocybin will be on the frontline in the battles against addiction, depression and mental health.
It has growth potential in the tens of billions.
And Revive is way ahead of the game.
https://revivethera.com/2020/08/revive-therapeutics-advancing-drug-delivery-technology-for-psychedelics-developed-prototypes-of-orally-dissolvable-thin-film-for-psilocybin/
$RVVTF Therapeutics will trump ineffective vaccines.
D614G mutation detected in M’sia – Noor Hisham https://harakahdaily.net/index.php/2020/08/16/d614g-mutation-detected-in-msia-noor-hisham/ via @harakahdailyHD
$RLFTF Therapeutics will trump ineffective vaccines.
D614G mutation detected in M’sia – Noor Hisham https://harakahdaily.net/index.php/2020/08/16/d614g-mutation-detected-in-msia-noor-hisham/ via @harakahdailyHD
Thanks.. I thieved it... and spread it around..
$RLFTF (copy) J-belfort DD
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status.
B) The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor.
What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials;
https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
C) Have you looked at who is on their data safety monitoring committee?
The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director.
You can’t truly believe these people would be involved in a pump and dump?
On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profile/658/alfred-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials is a heavyweight with a ton of big pharma experience and a wealth of government connections.
Dr. Ram (Chairman) is a leading analyst in the small cap biotech space. All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months.
Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close.
https://relieftherapeutics.com/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate individuals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually.
An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own.
Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
$RLFTF (copy) J-belfort DD
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status.
B) The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor.
What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials;
https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
C) Have you looked at who is on their data safety monitoring committee?
The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director.
You can’t truly believe these people would be involved in a pump and dump?
On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profile/658/alfred-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials is a heavyweight with a ton of big pharma experience and a wealth of government connections.
Dr. Ram (Chairman) is a leading analyst in the small cap biotech space. All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months.
Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close.
https://relieftherapeutics.com/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate individuals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually.
An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own.
Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
$RLFTF (copy) J-belfort DD
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status.
B) The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor.
What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials;
https://clinicaltrials.gov/ct2/results?cond=&term=aviptadil&cntry=&state=&city=&dist=
C) Have you looked at who is on their data safety monitoring committee?
The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director.
You can’t truly believe these people would be involved in a pump and dump?
On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profile/658/alfred-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials is a heavyweight with a ton of big pharma experience and a wealth of government connections.
Dr. Ram (Chairman) is a leading analyst in the small cap biotech space. All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months.
Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close.
https://relieftherapeutics.com/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate individuals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually.
An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own.
Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
$RLFTF Nice !! Right on Andy.
Quote:
RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol
I would like to know Which other drug has all three (bold above)?
https://www.neurorxpharma.com/press-releases/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells/
$RLFTF
all imho only
..just hit the ask and stop being cheap.
Going to dollars !!!
$RLFTF Today - Scientific and Medical Aspects of Dealing With COVID-19
78 Minutes
Join Meeting
This Sunday, August 16th, 2 pm ET; princeton78.com
(please note start time is different than the last 2 sessions)
What are the medical, pharmaceutical, and scientific communities doing to understand how COVID-19 operates, and to provide new treatments and vaccines that can lead us out of this pandemic?
Please join Stephen Chanock, Director of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI), who currently leads a project to learn who is more at risk for COVID-19 and what kinds of outcomes certain people are likely to incur, and Jonathan Javitt, CEO of U.S.-Israel-based NeuroRX, which just started Phase 2/3 clinical trials of RLF-100, a drug for the treatment of respiratory distress in COVID-19 patients.
This session will be moderated by Yale School of Medicine communicator and former CBS News producer and reporter Rob Forman. Log in at princeton78.com starting at 1:45 pm ET to catch up with classmates before we start the session!
As before, each session will run 78 minutes, and be a panel followed by a general discussion/Q&A. And all you need to do is login at the class website princeton78.com via Zoom – they’re free!
And we welcome your suggestions for topics. What would you would like to hear about, and which Classmates you would like to hear it from?
We look forward to you joining us.
https://princeton78.com/posts/feed.asp
$RLFTF Today - Scientific and Medical Aspects of Dealing With COVID-19
78 Minutes
Join Meeting
This Sunday, August 16th, 2 pm ET; princeton78.com
(please note start time is different than the last 2 sessions)
What are the medical, pharmaceutical, and scientific communities doing to understand how COVID-19 operates, and to provide new treatments and vaccines that can lead us out of this pandemic?
Please join Stephen Chanock, Director of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI), who currently leads a project to learn who is more at risk for COVID-19 and what kinds of outcomes certain people are likely to incur, and Jonathan Javitt, CEO of U.S.-Israel-based NeuroRX, which just started Phase 2/3 clinical trials of RLF-100, a drug for the treatment of respiratory distress in COVID-19 patients.
This session will be moderated by Yale School of Medicine communicator and former CBS News producer and reporter Rob Forman. Log in at princeton78.com starting at 1:45 pm ET to catch up with classmates before we start the session!
As before, each session will run 78 minutes, and be a panel followed by a general discussion/Q&A. And all you need to do is login at the class website princeton78.com via Zoom – they’re free!
And we welcome your suggestions for topics. What would you would like to hear about, and which Classmates you would like to hear it from?
We look forward to you joining us.
https://princeton78.com/posts/feed.asp
Countries will throw money at this for the solution to Covid-19 .. we're dealing with a different animal here .. nothing will go as usual..
This will be good for bringing in new buyers all around the World but the Truth is: Approved for compassionate use while going through FDA approval.. so I'll be sober in this announcement.. IMO
"A Swiss biotech company has obtained US approval for a Corona vehicle"
"The price increase followed the approval of the US Drug Administration (FDA) of Aviptadil tests"
$RLFTF: Explained: What is RLF-100 or Aviptadil, the 1970 drug being explored for Covid-19 treatment
Preliminary studies have shown that the drug RLF-100 protects alveolar type II cells that are responsible for oxygen exchange in lungs.
Written by Tabassum Barnagarwala , Edited by Explained Desk | Mumbai | Updated: August 15, 2020 11:02:25 am
RLF-100 is not a new finding. It was discovered in 1970 by Dr Sami Said, a pulmonary medicine specialist. At a testing centre in Pune. Express Photo by Ashish Kale
An old drug formulation — RLF-100 — is being probed to treat Covid-19 patients after initial studies have shown that the drug is able to halt SARS-CoV-2 virus replication in lungs. In Mumbai, doctors have begun prescribing this drug although it is not available in India.
What does RLF-100 do?
RLF-100, also called Aviptadil, is a formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP). VIP is released throughout the body, but remains mostly concentrated in lungs. It is produced by immune cells and nerve endings and acts as a neurotransmitter. It helps improve muscle activity and blood flow in gastrointestinal tract.
But it also plays another important function. Studies have shown VIP has anti-inflammatory and anti-cytokine activity properties. Preliminary studies have shown this protects alveolar type II cells that are responsible for oxygen exchange in lungs. Since coronavirus attacks lungs and the alveolar cells, the drug may be helpful in preventing SARS-CoV-2 onslaught in alveolar cell and limit damage in lung.
Houston Methodist Hospital was first to report recovery in a 54-year-old man who developed Covid-19 and became critical. The man had undergone a double lung transplant and later contracted Covid-19 infection. Doctors administered RLF-100 under emergency use and the patient could be weaned off ventilator in four days. “He received three infusions of RLF-100 under an FDA-approved emergency use IND (Investigational New Drug). Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted. He was discharged from intensive care at that point and returned home at 1 week on room air,” a multi-author article by doctors stated. This article is however not yet peer reviewed.
The clinical trial
RLF-100 has been granted “Orphan Drug Designation” by the US Food and Drug Administration (FDA) for Acute Respiratory Distress Syndrome and chronic lung diseases, drug maker NeuroRx said. On June 8, NeuroRx and Relief Therapeutics announced a phase 2/3 clinical trial to treat critical Covid-19 patients. The trial will have 144 participants. The drug will be targeted on those requiring high flow nasal oxygen, and those on non-invasive or invasive ventilator support. Doses for three successive days will be given to patients.
In a press statement earlier this month, CEO of NeuroRx Prof Jonathan Javitt said, “We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month.”
RLF-100 is not a new finding. It was discovered in 1970 by Dr Sami Said, a pulmonary medicine specialist. In 2001, US FDA gave RLF-100 an orphan drug designation to treat acute respiratory distress syndrome, and in 2006 for acute lung injury. US FDA also granted investigational new drug (IND) licenses for human trials of Aviptadil. But it has not shown significant progress in those trials in treating lung diseases.
Coronavirus Explained
What is Aviptadil, the 1970 drug being explored for Covid-19 treatment?
The lastest developments on Covid-19 vaccines
How are offshore oil rigs adapting to work during Covid-19?
CLICK HERE FOR MORE
Current use in Covid-19 treatment
There are still no well-designed clinical trials that have found optimistic findings for RLF-100 and research into its use to treat Covid-19 is in nascent stages. The manufacturer claims rapid clearance of pneumonia and improvement in oxygen levels in patients this drug was used on emergency basis.
In Mumbai, Breach Candy Hospital has prescribed this drug to a critically ill patient. The drug is currently not available in India. Kin of patient are trying to procure it from USA, treating doctors said.
Dr Rahul Pandit, intensivist in Fortis hospital, however warned. “There is very little known. For us to prescribe a drug, we need to wait for scientific evidence,” he said.
https://indianexpress.com/article/explained/explained-what-is-rlf-100-or-aviptadil-the-1970-drug-being-explored-for-covid-19-treatment-6555659/
$RLFTF: Explained: What is RLF-100 or Aviptadil, the 1970 drug being explored for Covid-19 treatment
Preliminary studies have shown that the drug RLF-100 protects alveolar type II cells that are responsible for oxygen exchange in lungs.
Written by Tabassum Barnagarwala , Edited by Explained Desk | Mumbai | Updated: August 15, 2020 11:02:25 am
RLF-100 is not a new finding. It was discovered in 1970 by Dr Sami Said, a pulmonary medicine specialist. At a testing centre in Pune. Express Photo by Ashish Kale
An old drug formulation — RLF-100 — is being probed to treat Covid-19 patients after initial studies have shown that the drug is able to halt SARS-CoV-2 virus replication in lungs. In Mumbai, doctors have begun prescribing this drug although it is not available in India.
What does RLF-100 do?
RLF-100, also called Aviptadil, is a formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP). VIP is released throughout the body, but remains mostly concentrated in lungs. It is produced by immune cells and nerve endings and acts as a neurotransmitter. It helps improve muscle activity and blood flow in gastrointestinal tract.
But it also plays another important function. Studies have shown VIP has anti-inflammatory and anti-cytokine activity properties. Preliminary studies have shown this protects alveolar type II cells that are responsible for oxygen exchange in lungs. Since coronavirus attacks lungs and the alveolar cells, the drug may be helpful in preventing SARS-CoV-2 onslaught in alveolar cell and limit damage in lung.
Houston Methodist Hospital was first to report recovery in a 54-year-old man who developed Covid-19 and became critical. The man had undergone a double lung transplant and later contracted Covid-19 infection. Doctors administered RLF-100 under emergency use and the patient could be weaned off ventilator in four days. “He received three infusions of RLF-100 under an FDA-approved emergency use IND (Investigational New Drug). Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted. He was discharged from intensive care at that point and returned home at 1 week on room air,” a multi-author article by doctors stated. This article is however not yet peer reviewed.
The clinical trial
RLF-100 has been granted “Orphan Drug Designation” by the US Food and Drug Administration (FDA) for Acute Respiratory Distress Syndrome and chronic lung diseases, drug maker NeuroRx said. On June 8, NeuroRx and Relief Therapeutics announced a phase 2/3 clinical trial to treat critical Covid-19 patients. The trial will have 144 participants. The drug will be targeted on those requiring high flow nasal oxygen, and those on non-invasive or invasive ventilator support. Doses for three successive days will be given to patients.
In a press statement earlier this month, CEO of NeuroRx Prof Jonathan Javitt said, “We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month.”
RLF-100 is not a new finding. It was discovered in 1970 by Dr Sami Said, a pulmonary medicine specialist. In 2001, US FDA gave RLF-100 an orphan drug designation to treat acute respiratory distress syndrome, and in 2006 for acute lung injury. US FDA also granted investigational new drug (IND) licenses for human trials of Aviptadil. But it has not shown significant progress in those trials in treating lung diseases.
Coronavirus Explained
What is Aviptadil, the 1970 drug being explored for Covid-19 treatment?
The lastest developments on Covid-19 vaccines
How are offshore oil rigs adapting to work during Covid-19?
CLICK HERE FOR MORE
Current use in Covid-19 treatment
There are still no well-designed clinical trials that have found optimistic findings for RLF-100 and research into its use to treat Covid-19 is in nascent stages. The manufacturer claims rapid clearance of pneumonia and improvement in oxygen levels in patients this drug was used on emergency basis.
In Mumbai, Breach Candy Hospital has prescribed this drug to a critically ill patient. The drug is currently not available in India. Kin of patient are trying to procure it from USA, treating doctors said.
Dr Rahul Pandit, intensivist in Fortis hospital, however warned. “There is very little known. For us to prescribe a drug, we need to wait for scientific evidence,” he said.
https://indianexpress.com/article/explained/explained-what-is-rlf-100-or-aviptadil-the-1970-drug-being-explored-for-covid-19-treatment-6555659/
(copy) from intheknow.. kinda applies here: so RLFTF timelines will be unpredictable (pushed forward) IMO especially with compassionate use access.
A drug that receives Fast Track designation is eligible for some or all of the following:
More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval
More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers
Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met
Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA
Once a drug receives Fast Track designation, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.
Relief Therapeutics - diabetic complications and respiratory diseases.
Relief Therapeutics Holding AG is a specialty pharmaceutical company. The Company is focused on the development of treatment for diabetic complications and respiratory diseases.
(diabetic complications) ...wonder if one of the bigger pharma's who are looking to get involved are also involved with Mannkind Corp. MKND and after we/they get a few bucks that inhaled insulin will be something to partner in on.. // diabetic complications and respiratory diseases. //
..maybe the big dogs will put in for a share buyback and move this to NASDQ
~ Money Making Money ~
SWX: RLF
0.48 CHF +0.100 (26.25%)
Aug 14, 4:13 PM GMT+2
$RVVTF Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19 https://www.globenewswire.com/news-release/2020/08/14/2078641/0/en/Revive-Therapeutics-Signs-MOU-with-Attwill-Medical-Solutions-for-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html
$RVVTF Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19 https://www.globenewswire.com/news-release/2020/08/14/2078641/0/en/Revive-Therapeutics-Signs-MOU-with-Attwill-Medical-Solutions-for-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html
$RLFTF That's what I was thinking...
RE: "The word “All” does that mean everyone that is critical will get this drug? If so, this is Humungous news!!
$RLFTF Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to all patients with Critical COVID-19 and Respiratory Failure | PharmaShots https://pharmashots.com/press-releases/relief-therapeutics-and-neurorx-expand-clinical-trial-of-rlf-100-to-all-patients-with-critical-covid-19-and-respiratory-failure/
$RLFTF Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to all patients with Critical COVID-19 and Respiratory Failure | PharmaShots https://pharmashots.com/press-releases/relief-therapeutics-and-neurorx-expand-clinical-trial-of-rlf-100-to-all-patients-with-critical-covid-19-and-respiratory-failure/
..and can be called earlier if the proof is overwhelming...
SWX: RLF
0.44 CHF +0.058 (15.22%)
Aug 14, 12:52 PM GMT+2
$RLFTF COVID-19 therapeutics tracker https://scq.io/96nAk4p
$RVVTF COVID-19 therapeutics tracker https://scq.io/96nAk4p
wow you're a real specialist (( I did NOT say anyone mentioned RVVTF ))
tendie 3 hots and a cot... soon